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PR
ONanoﬁbrous materials produced by electrospinning processes have attracted considerable interest in tissueregeneration, including bone reconstruction. A range of novel materials and processing tools have been
developed to mimic the native bone extracellular matrix for potential applications as tissue engineering
scaffolds and ultimately to restore the degenerated functions of the bone. Degradable polymers, bioactive
inorganics and their nanocomposites/hybrids nanoﬁbers with suitable mechanical properties and bone
bioactivity for osteoblasts and progenitor
^
/stem cells have been produced. The surface functionalization with
apatite minerals and proteins/peptides as well as drug encapsulation within the nanoﬁbers is a promising
strategy for achieving therapeutic functions with nanoﬁbrous materials. Recent attempts to endow a 3D
scaffolding technique to the electrospinning regime have shown some promise for engineering 3D tissue
constructs. With the improvement in knowledge and techniques of bone-targeted nanoﬁbrous matrices,
bone tissue engineering is expected to be realized in the near future.
© 2009 Published by Elsevier B.V.356E
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1. Introduction
The treatment of bone defect sites with medical-grade materials is
widely performedwith some degree of clinical success. Themanipula-
tion of biomaterials in concert with tissue cells is considered a
promising and alternative therapy to the autologous surgery [1]. This
tissue engineering approach to bone reconstruction, having gained
signiﬁcant interest and research input over the last decade, requires a
suitable cell supporting matrix, namely a scaffold, to provide a 3-
dimensional substrate for cells to populate on and function appro-
priately during the formation of bone analog tissue [2,3].
There have been signiﬁcant advances in the development of bone
scaffolds with various compositions and 3-dimensional conﬁgurations
using a variety of techniques [4,5]. Recently, the electrospinning
process and the nanoﬁbrous matrices thus fabricated have gained
tremendous interest, mainly due to the structural similarity to the
tissue extracellular matrix (ECM), the processing availability to a wide
range of materials, as well as simple set-up and operation at low cost
[6–10]. Several studies have reported the performance of nanoﬁbrous
materials in guiding cells to initially adhere to and spread over the
material, as well as further triggering them to secrete the appropriate
ECM molecules targeted to the skin, blood vessel, cartilage, muscle,
adipose, nerve and bone. The intriguing features of a ﬁbrous
morphology with diameters ranging from tens of nanometers to a
few micrometers have attracted considerable attention focused on
exploiting the properties as well as structural tuning to the tissue of
concern for the applications as a tissue engineering scaffold.
In the bone reconstruction area, the electrospun nanoﬁbers have
also attracted considerable attention from scientists aimed at
identifying suitable material compositions and exploiting them into
electrospinning [11,12]. As the bone-associated cells and their
progenitor/stem cells show initial responses in a similar manner to
those in other tissue cells, which are anchorage-dependent, the
nanoﬁbrous substratum may provide favorable conditions for cell
anchorage and growth. In tandem with the initial cell responses,
further osteoblastic differentiation and mineralization have also been
reported to be regulated in a positive manner on nanoﬁbrous surfaces
compared to a dense substrate of polymers [13].
Although studies on the in vivo feasibility of electrospun nanoﬁbers
in bone reconstruction and tissue engineering progress are currently in
the early stages, recent reports of electrospun nanoﬁbers with new
compositions targeted for bone aswell as someprocessing tools to design
3-dimensional scaffolding and tissue engineering have highlighted the
potential use of electrospun materials in bone tissue engineering.
This review consists of three parts: a brief introduction of the bone
structure,which is to bemimickedbyelectrospunnanoﬁbrousmatrices,
and the bone tissue engineering concept; a research summary of
electrospun materials targeted for bone regeneration, including poly-
mers, inorganics and their composites/hybridized compositions; and a
description of on-going efforts aimed at employing nanoﬁbrousUN
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matrices for drug delivery and tissue engineering, whichwas facilitated
by surface functionalization, drug encapsulation and 3D scaffolding
technique.
2. Bone and tissue engineering
2.1. Bone structure and ECM mimics
2.1.1. Bone structure: bone cells, ECMs and organization
It is important to understand the biomechanical and biological
properties of bone in order to gain insight into choosing the type
of materials that can best be used to reconstruct the degenerative
functions of bone. Bone is a complex, highly organized and specialized
connective tissue. Compared to soft tissues, bone is physically hard, rigid
and strong, and microscopically contains relatively few cells with
abundant intercellular matrix in the form of collageneous ﬁbers and
stiffening inorganic substances. There are three types of cells comprising
bone as illustrated in Fig. 1.
Osteoblasts located on the surfaces of bone are responsible for the
formation and organization of the extracellular matrix of bone and its
subsequent mineralization. These cells are responsible for the
synthesis of organic components of the bone ECM. They are derived
from mesenchymal precursor cells in the marrow, which also has the
potential to differentiate into fat cells, chondrocytes or muscle cells
[14]. The principal products of mature osteoblast are type I collagen
(90% of the protein in bone), bone speciﬁc vitamin-K dependent
proteins, osteocalcin and matrix Gla protein, phosphorylated glyco-
proteins including bone sialoproteins I and II, osteopontin and
osteonectin, proteoglycans and alkaline phosphatase.
A proportion of osteoblasts become trapped as osteocytes in the
lacunae within the bone matrix. These cells may be responsible for
intercellular communication. They possess long thin cytoplasmic
processes called ﬁlopodia located in thin cylindrical spaces or canals in
the bonematrix. Nutrients and oxygen pass between the blood vessels
and distant osteocytes via the arrangement of the canaliculi.
Osteocytes also break down the bone matrix through osteocytic
osteolysis to release calcium for calcium homeostasis [15].
Osteoclasts are polarized cells with a rufﬂed border region of the cell
membrane that is surrounded by an organelle-free region, or ‘clear
zone’. They adhere to the bone surface via integrins, which are
specialized cell surface receptors [16]. Osteoclastic bone resorption
initially involves mineral dissolution, followed by degradation of the
organic phase. These processes take place beneath the rufﬂed border
and depend on lysosomal enzyme secretion and an acid microenviron-
ment [17]. Osteoclasts actively synthesize lysosomal enzymes, particu-
larly the tartrate-resistant isoenzyme of acid phosphatase (TRAP) (used
as amarker of the osteoclast phenotype), and cysteine-proteinases, such
as cathepsins, which are capable of degrading collagen. Lysosomal
enzymes are released only at the rufﬂed border region of the osteoclast
cell membrane [18].e structure at cellular level.
ential platforms for bone tissue engineering, Adv. Drug Deliv. Rev.
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2.1.2. Bone ECM components
Type I collagen is a major organic component of mineralized ECM,
comprising 90–95% of the organic material and serves as a template
upon which mineral is deposited. Type V collagen is also present in
small quantity, as are a number of non-collageneous proteins, some of
which are relatively speciﬁc to bone [19].
In addition to themajor collagenmatrix, bone contains several other
non-collageneous proteins. Osteocalcin is a 6-kDa noncollageneous
protein and comprises up to 15% of the noncollageneous protein of the
mature bone [20]. The osteocalcin expression is largely restricted to the
osteoblasts of bone as well as the odontoblasts and cementoblasts of
teeth [21]. The structure of osteocalcin is characterized by three
glutamic acid residues that undergo vitamin K-dependent carboxyla-
tion. The γ-carboxyglutamic acid residues (Gla) provide osteocalcin
with the ability to bind bone mineral hydroxyapatite with high afﬁnity
[22]. Osteocalcin is the second most abundant protein in the bone
matrix, and it is highly conserved in all vertebrate species [23]. The
biological function of osteocalcin is probably related to the regulation of
bone turnover and/or mineralization [24].
Osteopontin is a secreted, glycosylated phosphoprotein that is
found normally in mineralized tissues, such as bones and teeth, in
addition to the kidneys, urine and epithelial lining cells in numerous
organs [25]. Osteopontin supports cell adhesion through its Arg-Gly-
Asp (RGD) integrin recognition motif. Osteopontin is also rich in
aspartic acid residues and can be heavily glycosylated. The acidic
nature of osteopontin probably accounts for its ability to modulate
the growth of calcium crystals in both bone [26] and urine [27].
Osteopontin is a multifunctional protein that promotes cell adhesion
and migration, inhibits bone mineral formation, and binds Ca2+
[28,29] Osteopontin can exist in a variety of forms depending on the
extent of post-translational modiﬁcation. A highly phosphorylated
form of osteopontin can be isolated from themineralized extracellular
matrix of bone tissue, and is synthesized by osteoblasts [30].
The ECM plays an important role in the function of growth factors
[31]. This cooperative/synergistic process may involve the conver-
gence of intracellular signaling pathways triggered by the ECM
proteins and growth factors, and becomes important in the tissue
regeneration process. In addition to its serving as a scaffolding for
mineralization, the ECM proteins function as a substratum for bone
cell adhesion and differentiation. Once engaged with the matrix, the
bone cells sense deformation and other changes within the bone
(matrix-cell crosstalk) [32]. On the other hand, theymay interact with
their surroundings by anchoring and pulling on the matrix, as has
been shown for other cell types (cell–matrix crosstalk) [33]. The
summary of the bone ECM proteins is shown in Table 1.
2.1.3. ECM mimicking approach
Given that defective bone can recover with the use of artiﬁcial
materials, bone-associated cells should be directed to recognize and
respond appropriately to form bone ECM that is analogous to the
native bone matrix. Therefore, it is favored to design and engineer
materials with structure, composition and properties similar to theUN
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Table 1
The ECM proteins found in bone.
ECM proteins Function Comments
Collagens Collagen type I Tensile strength 90% of total
bone proteinCollagen type V Tensile strength
Noncollagen proteins Osteocalcin
(bone Gla protein)
Mineralization
Osteopontin Cell adhesion,
Mineralization
Bone sialoprotein-1
Bone sialoprotein-2 Mineralization
Osteonectin (SPARC) Cell adhesion
Fibronectin Cell adhesion
Thrombospondin Cell adhesion
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bone ECM [34]. Bone mimicking materials should play active roles in
assisting cells to follow processes that are effective in bone formation.
The major organic bone matrix consists of collageneous ﬁbrils
interwoven within hydrated polysaccharide chains, acting efﬁciently
in response to external stress, and transmitting signals to the cell
membrane receptors that reach the nucleus via intracellular signaling
cascades. More importantly, within the organic network, inorganic
nanocrystallites (mostly hydroxyapatite phase) are mutually incor-
porated. Therefore, the bone ECM is a type of organic–inorganic
nanocomposite, organized on the nanoscale, in which bone is allowed
to perform good biomechanical functions and biological roles [35].
Besides collageneous ﬁbers and inorganic mineral nanocomponents, a
variety of key proteins and growth factors are present in the bone
matrix and are involved in bone formation, and should also be
considered in the design of ECM mimicking materials. Overall, a
nanoﬁbrous matrix that can be produced by electrospinning is
believed to be able to retain bone ECM components and be engineered
to modulate the microenvironments further to form tissue mimics in
the course of ex vivo tissue engineering or under in vivo situations
[36]. This drives us to focus on a tissue engineering approach where
the native bone structure can be better mimicked because bone
actually contains both ECM and cell components.
2.2. Bone tissue engineering
2.2.1. Progenitor/stem cells
The recent emerging strategy in bone tissue engineering is to use
stem cells. Many adult tissues contain populations of stem cells that
have the capacity for renewal. These cells may be found within the
tissue or in other tissues that serve as stem cell reservoirs. For example,
although bone marrow is a major source of adult hematopoietic stem
cells (HSCs) that renew circulating blood elements, these cells can also
be found in other tissues [37]. Adult bone marrow also contains
mesenchymal stem cells (MSCs), which contribute to the regeneration
of mesenchymal tissues, such as bone, cartilage, muscle, ligament,
tendon, adipose, and stroma [38]. Therefore, they are an attractive
cellular source for bone tissue engineering applications. Under
permissive stimulation, MSCs undergo osteogenic differentiation
through a well-deﬁned pathway, acquiring osteoblastic markers and
secreting extracellular matrix and calcium crystals [39]. In vitro and
animal implantation studies have suggested that the population is
either multipotent MSCs or mixtures of committed progenitor cells,
each with a restricted potential [40]. However, clinical translation is
impeded by the low population of MSCs in bone marrow, particularly
in older age groups in whom fractures and non-union are common.
Blood mesenchymal precursor cells (BMPCs) have been a central
focus in regenerative medicine for bone regeneration ever since these
cells were ﬁrst found to exist in the circulation of healthy patients.
BMPCswere discovered by Zvaiﬂer et al., who reported that these cells
adhere to plastic and glass and proliferate logarithmically in DMEM-
^
20% fetal calf serumwithout growth factors, which suggests that these
cells are relatively easy to expand in vitro [41]. After adding osteogenic
supplements (e.g., dexamethasone, ascorbic acid, and beta-glycer-
ophosphate) into the culture, ﬁbroblast formation is inhibited, and the
BMPCs then assume the more cuboidal shape of osteoblasts, as
conﬁrmed by alkaline phosphatase (ALP) and osteocalcin staining.
This group further demonstrated that circulating osteocalcin positive
cells also deposit minerals in vitro and bone in vivo in immunodeﬁ-
cient mice [42]. They also reported that circulating osteocalcin
positive cells are predominantly small, round cells that are phenoty-
pically similar to the cells originally isolated from the nonadherent
bone marrow population by Long et al. [43]. Given the osteogenic
potential of circulating blood mesenchymal cells, exposing these cells
to osteogenic factors is a potent stimulus for bone formation. Otsuru
et al. recently reported that osteoblast progenitor cells in the
circulation that originate from the blood mesenchyme form ectopicential platforms for bone tissue engineering, Adv. Drug Deliv. Rev.
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(BMP)-2-containing collagen pellet into skeletal muscle beds of mice
[44].When these pellets were implanted into GFP transgenic mice,
there was a signiﬁcant number of GFP-positive osteoblastic cells
engrafting into the ectopic bone after circulatory migration to the
osteogenic site.
More recently, MSCs with osteogenic potential have been isolated
from a wide variety of tissue types, including adipose tissue, umbilical
cord blood, amniotic ﬂuid and fetal blood [45,46]. However, it is
unclear how these novel fetal perinatal and adult MSC sources
compare with their standard adult blood MSC counterparts for
osteogenic differentiation and potential for bone tissue engineering.
2.2.2. Osteogenesis and angiogenesis
The development of osteogenesis occurs through two distinct
processes: intramembranous and endochondral ossiﬁcation. In intra-
membranous ossiﬁcation, bone is formed by the differentiation of
mesenchymal cells into osteoblasts in the absence of a cartilaginous
model. The ﬂat bones of the skull, sternum, and scapula are examples
of bones that develop through intramembranous ossiﬁcation. The
term endochondral refers to the close association of the developing
bone with the pre-existing hyaline cartilage model of that bone. The
long bones of the limbs (including the phalanges) and ribs develop
through endochondral ossiﬁcation.
Recently, studies using in vitro and in vivo models of osteogenesis
highlighted the importance of blood vessels in the formation of theUN
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Table 2
Summary of electrospun nanoﬁber systems produced for the bone reconstruction.
Composition Fiber diameter Assays
Synthetic polymers PLA (L- and DL-type) 141–2140 nm MC3T3-E
PCL 20–5000 nm BMSC, in
PHB, PHBV, blend 2000–4300 nm SaOS-2 &
Natural polymers Collagen I 50–1000 nm hMSC
Chitosan 200 nm MG63, in
Silk ﬁbroin 217–610
^
/
^
183–810 nm MC3T3-E
Silk ﬁbroin 700 nm BMSC
Polymer blends PCL–gelatin tens of nm–1000 nm BMSC
PLLA–gelatin 190–390 nm MC3T3-E
PCL–heparan sulfate – BMSC
Inorganics Bioactive glass 84–630 nm Productio
Bioactive glass 320 nm Productio
Hydroxyapatite and
ﬂuoro-hydroxyapatite
240–1550 nm Productio
Hydroxyapatite 10–30 mm Productio
Hydroxyapatite 200–500 nm Processin
Silicate – In vitro (
Composites
^
/
^
hybrids Gelatin–hydroxyapatite 200–400 nm Productio
Collagen–hydroxyapatite 75–160 nm Productio
Chitosan–hydroxyapatite ∼214 nm hFOB
PCL–CaCO3 ∼760 nm Mechani
PLLA–hydroxyapatite ∼1000–2000 nm Productio
Siloxane–gelatin 40 to 670 nm Productio
PCL–HA–collagen ∼370 nm hFOB
PCL–βTCP 200–2000 nm Osteobla
Surface functionalized PCL ∼250 nm Productio
ﬁbroblas
PLLA 200–2200 nm Productio
PDLLA – Productio
PLLA, PLLA–collagen 287–
^
364 nm hFOB
PLGA, PLGA–PEG – Fibroblas
Drug
^
/
^
gene delivery PLA, PCL – Antibacte
Silk, Silk-PEO
(+hydroxyapatite)
510–590 nm hMSC res
PLGA–HA 250–875 nm In vitro g
Abbreviations; PLA: poly(lactic acid), PCL: poly(ε-caprolactone), PHB: poly(hydroxybutyric
PEO: poly(ethylene oxide), PEG: poly(ethylene glycol), β-TCP: β-tricalcium phosphate, HA:
hFOB: human fetal osteoblast.
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skeleton and bone repair [47]. The vasculature transports oxygen,
nutrients, soluble factors and numerous cell types to the bone tissues.
There are a number of factors involved in angiogenesis, and the main
factors are Vascular Endothelial Growth Factor (VEGF), Fibroblast
Growth Factor-2 (FGF-2), and various members of the Transforming
Growth Factor beta (TGF-β) family [48]. Recent studies have shown
that a combination of angiogenic and osteogenic factors can stimulate
bone repair and regeneration [49]. Therefore, the delivery a combined
system of growth factors at different rates locally from an engineered
biodegradable nanoﬁbrous scaffold might enhance the reparative
mechanism of critical sized bone defects, thereby mimicking the in
vivo bone repair conditions. The multiple release of growth factors,
such as VEGF and BMP, may mimic the conditions in bone fracture
repair. Hence, scaffolds capable of releasing an active angiogenic
factor will promote early vascularization and attract osteogenic
precursor cells. Huang et al. reported that PLGA scaffolds containing
a combination of plasmids encoding DNA for BMP-4, VEGF and human
bone marrow stromal cells promoted greater bone formation when
implanted into the subcutaneous tissue of SCID mice than those
containing a single factor or a combination of two factors [50].
2.2.3. Bone tissue engineering
Bone tissue engineering has become a rapidly expanding research
area because it offers a new and promising approach for bone repair
and regeneration [51]. Typically, bone tissue engineering approaches
involve the use of scaffolding materials in combination with tissueTE
D
PR
Remarks Ref.
1 Effect of osteogenic factors and ﬁber size [55]
vivo (rat) Tissue engineering [11,54]
L929 [56]
[63]
vivo (rabbit) Bone formation at 4 weeks [69]
1 [66]
Poly(ethylene oxide) (PEO) addition [65]
Cell penetration with gelatine addition [57]
1 Enhanced cell responses on blends [58]
Osteogenic differentiation [59]
n, bone bioactivity, rBMSC Excellent bone bioactivity and BMSC responses [70]
n, osteoblast adhesion FN-introduction, enhanced cell adhesion [75]
n, dissolution Reduced dissolution by ﬂuorine addition [71]
n Microﬁbers [72]
g [73]
MG63) Apatite forming ability [74]
n, osteoblasts Enhanced osteoblastic differentiation [79]
n, osteoblasts [80]
PEO addition [81]
cal test, in vitro (hFOB) GBR membrane application [82]
n, MG63 Surfactant introduction [83]
n, MC3T3-E1 Hybridized structure, Ca requirement [84]
[85]
st responses Better cell adhesion due to βTCP [86]
n, osteoblasts, PDL
ts
Apatite mineralized, higher osteogenic
responses
[87]
[88]
n NaOH-treatment [89]
n Ca(NO3)2 addition [90]
Mineralization with collagen [91]
t adhesion Amination, RGD-immobilization [94]
rial effects Antibiotic delivery [96]
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Fig. 2. (a) PCL electrospun nanoﬁber. (b1,b2) Histology cross-section of the explanted
specimens after 4 weeks of in vitro culture and 4 weeks of implantation in the
omentum of rat. (b1) Osteocyte-like cells embedded in bone matrix are present (H&E;
original magniﬁcation, ×3100). (b2) Mineralization has occurred throughout the
specimen (von Kossa; original magniﬁcation, ×3100). Adapted with permission from
[54] copyright 2004 Mary Ann Liebert.
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cells and biological cues. An advanced scaffolding material for tissue
engineering must exhibit high quality, reliability, sustainability and
cost-effectiveness throughout the individual's life and provide new
advanced levels of medical assistance in therapy and surgery. One
particular requirement of bone tissue engineering is that the scaffold
be porous because large numbers of cells can be incorporated in that
form. The three dimensional scaffolds provide the necessary support
for cells to attach, grow and differentiate, and deﬁne the overall shape
of a bone tissue engineered transplant [1]. A range of biomaterials
have been investigated for use in bone tissue engineering scaffolds,
which can be classiﬁed mainly into three categories according to the
composition: bioactive inorganics, degradable polymers and their
composites/hybridized forms [52]. Gigante et al. evaluated the
behavior of human MSCs cultured on various scaffolds to determine
if their differentiation can be induced by cell–matrix interactions [53].
They reported that MSCs grown on type I+II collagen differentiated
to cells expressing chondrocyte markers, while those grown on type I
collagen+hydroxyapatite differentiated into osteoblast-like cells.
Their study highlighted that human MSCs grown on different scaffold
matrices can display different behaviors in terms of cell proliferation
and phenotype expression [53].
Recent technological advances has facilitated the generation of a
variety of scaffolds with a modulated pore conﬁguration and nano-
structure. Electrospun nanoﬁbers are one of these recently highlighted
systems that may ﬁnd applications as a scaffolding material in bone
tissue-engineered constructs.
3. Electrospun bone regenerative materials
Designing matrices suitable for the recruitment of osteoprogeni-
tor/stem cells has been promoted by the approach of mimicking the
composition, morphological traits and mechanical function of the
native bone ECM. The beneﬁcial features of a nanoﬁbrous structure by
electrospinning were ﬁrst realized with degradable polymers, which
stimulate cells into osteogenic pathway assisted via well-controlled
differentiation cues.
However, a major part of the bone ECM also contains calcium
phosphates mineral phases, which requires a mineralization step that
is essential in the bone regeneration process. The existence of bone-
bioactive inorganic components within biomaterials generally favors
calcium phosphate mineralization followed by an osteogenic differ-
entiation process. Therefore, recent studies have focused on introdu-
cing a range of inorganic phases within the polymeric nanoﬁbers with
the ultimate aim of achieving both bone-speciﬁc bioactivity and
mechanical properties.
A new strategy to designing nanoﬁbers involves endowing bio-
functionality onto the surface of nanoﬁbers because the cells ﬁrst
recognize the surface of the material, which mostly regulates their
responses. Modulation of a polymeric surface with materials that are
more friendly and active to bone cells, such as a bone mineral-like
phase, is one example of surface tailoring methods targeted for bone
regeneration. Moreover, nanoﬁbers that are surface-conjugated or
incorporated internally with proteins and genes are an elegant way of
utilizing nanoﬁbrous matrices in drug delivery systems. In vitro data
have demonstrated the potential of introducing cell adhesive proteins
or peptides as well as osteogenic stimulatory signals including growth
factors and genes. In Table 2, the electrospun nanoﬁber systems
produced for the reconstruction of bone tissue are summarized.
Because of the inherent processing nature of electrospinning,
which contains pores with sizes at best a few micrometers, the
introduction of larger sized pores within the nanoﬁbrous network are
needed in order to identify extended and potential uses of bone tissue
engineering 3D scaffolds. A few recent trials carried out to generate
macro-sized pores and engineer 3D tissue constructs provided some
insights into future work on bone tissue engineering using electro-
spun nanoﬁbers as a scaffold.Please cite this article as: J.-H. Jang, et al., Electrospun materials as pot
(2009), doi:10.1016/j.addr.2009.07.0083.1. Polymeric nanoﬁbers
The electrospinning of degradable polymers, either with a
synthetic or natural origin, was ﬁrst reported to generate suitable
bone cell matrices largely due to their ease of processing including
solution preparation. Furthermore, the ﬂexibility and shape-avail-
ability of polymeric materials gives them great potential in the bone
regeneration area.
Among all polymeric materials, a group of poly(α-hydroxyl acid),
such as poly(lactic acid) (PLA), poly(glycolic acid) (PGA), poly(ε-
caprolactone) (PCL) and their copolymers, has been the most
extensively studied nanoﬁber system for the regeneration of tissues,
including bone [3]. PCL was ﬁrst suggested to be a degradable
nanoﬁber matrix for the bone regeneration [11], which demonstrated
good support of the rat bone marrow stromal cells (rBMSCs) and in
vitro matrix formation at 4 weeks, such as collagen I and calcium
phosphate mineral. Moreover, a cell-nanoﬁber construct implanted inential platforms for bone tissue engineering, Adv. Drug Deliv. Rev.
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rat omenta for 4 weeks revealed the formation of collagen I and
mineralization similar to bone-like ECM, highlighting its usefulness in
bone tissue engineering (Fig. 2) [54]. The PLA electrospun nanoﬁbers
with variable sizes were observed to affect the MC3T3-E1 cell
responses [55]. Interestingly, when an osteogenic medium was
used, a higher cell density was observed on the PLA nanoﬁbers than
on ﬂat PLA. On the other hand, there was little difference observed
when no osteogenic medium was used, suggesting the possible
inﬂuence of osteogenic factors on the osteoblastic responses to the
nanoﬁbrous topology. Poly(hydroxyalkenoate)s, another class of
degradable polyester polymer, was also developed into electrospun
nanoﬁbers for bone regeneration [56]. Poly(hydroxybutyrate) (PHB)
and poly(hydroxybutyrate-co-hydroxyvalerate) (PHBV) nanoﬁbers
with relatively large diameters (approximately 2 to 4 µm on average)
exhibited better cell growth behavior (SaOS-2 cell line) than their
equivalent ﬂat ﬁlm counterparts, and maintained the osteoblastic
phenotype [56].
However, due to the innate hydrophobic nature, the initial cell
adhesion behavior to the synthetic polymers is limited. Given that
nanoﬁbers are to be used as cell matrices for tissue engineering, it is
essential to conﬁrm the initial cell adhesion and high population.
Blending with natural polymers is another way of improving the cell
compatibility [57,58]. When PCL was mixed with gelatin at a 1:1 ratio,
the blending nanoﬁber exhibited good penetration of BMSCs within
the nanoﬁber matrix. On the other hand, there was little growth
observed within the pure PCL nanoﬁber [57]. Our recent study on the
blending nanoﬁbers of PLA with gelatin at various ratios (1:3, 1:1 and
3:1) showed that the osteoblastic cells (MC3T3-E1) were more viable
than those on pure PLA nanoﬁber [58]. Moreover, a range of bone-
related genes were expressed at signiﬁcantly higher levels on a
blended hydrophilic nanoﬁber substrate. Another report developed
heparan sulfate-containing PCL nanoﬁbers, where human MSCs pre-
committed to an osteogenic lineage were observed to secrete bone
matrix and bone formation under a subcutaneous model in nude mice
[59]. Together with the blending approach, the surface of the
synthetic nanoﬁbers was coated with natural polymers, such as
collagen and gelatin, which showed good initial adhesion and growth
of cells including osteoblasts [60,61].
As natural polymer sources, collagen has long been studied for the
electrospinning into nanoﬁbers [62–64]. Type I collagen is the major
organic component of bone ECM, and has attracted considerable
attention for use as a bone cell supporting matrix. Nanoﬁbers of
collagen type I can be electrospun to various diameters and provide
good substrate conditions for BMSCs to adhere and grow [63].UN
CO
RR
Fig. 3. (a) chitosan nanoﬁbrous membrane. (b,c) histological view of implantation without t
at 4 weeks (arrows: defect margin, NB: new bone, M:membrane). H & E staining in (b) andM
2007 American Academy of Periodontology.
Please cite this article as: J.-H. Jang, et al., Electrospun materials as pot
(2009), doi:10.1016/j.addr.2009.07.008TE
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Although electrospun collagen mimics the nanoﬁbrous morphology
of native ECM, there is some debate as to whether the native structure
and biological characteristics are preserved [64]. Whilst one report
showed native periodic bands in electrospun collagen [62], Jeugolis
et al. insisted the electrospun collagen was only a denatured form
gelatin, when electrospun out of ﬂuoroalcohols which limit the typical
biological properties of collagen derived from the triple helical
structure, and suggested the method of collagen coating of the
electrospun nanoﬁbers [64]. Nevertheless, cross-linked electrospun
collagen is believed to have strong potential as a nanoﬁbrous
substrate for cells to anchor and populate as well as in osteogenic
development and mineral deposition provided appropriate differ-
entiation cues are present.
Silk ﬁbroin has also been explored as a potential electrospun
substrate because of its useful properties for tissue engineering, such
as cell compatibility, biodegradability and minimal inﬂammatory
reaction [65]. Electrospun nanoﬁbers of silk with sizes ranging from
500 nm to 1 µm were observed to support the initial adhesion and
growth of BMSCs [65] and osteoblastic cells [66]. One merit of silk
ﬁbroin in bone regeneration is its ability to promote the deposition of
calcium phosphate minerals thus to form an apatite–silk nanocom-
posite [67].
Compared to other natural polymers, chitosan is considered
relatively difﬁcult to electrospin mainly due to the limited solvents
and high viscosity at low concentrations [68]. A recent study
developed an electrospun chitosan nanoﬁbrous mesh for use as a
dental barrier membrane to selectively guide hard tissues within the
periodontal pocket. The in vivo result at 4 weeks of implantation using
the membrane within a critical-sized defect of a rabbit calvarium
demonstrated almost full coverage of the defect and bone formation,
which highlights its potential use in bone regeneration (Fig. 3) [69].
3.2. Inorganic nanoﬁbers
Although the degradable polymeric nanoﬁbers with a synthetic or
natural origin have been shown to support the growth of osteoblasts
and their progenitor/stem cells as well as to recruit their phenotypic
expression and differentiation under the appropriate microenviron-
ment, bone-bioactive inorganics, including calcium phosphates and
bioactive glasses/glass ceramics have been a fascinating choice of
materials for the reconstruction of hard tissues. In practice, the
electrospinning of inorganic materials into a nanoﬁbrous structure is
well documented, even though they were mainly not for biomedical
purposes. It was not until a few years ago that some studies exploitinghe membrane (b) and (c) with the chitosan membrane within a rabbit calvarium defect
asson-Trichrome–Goldner staining in (c). Adaptedwith permission from [69] copyright
ential platforms for bone tissue engineering, Adv. Drug Deliv. Rev.
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were reported.
A recent study reported the generation of bioactive glass nanoﬁbers
by electrospinning [70]. Silica-based sol–gel glass (70SiO2·25CaP·5P2O5)
mixed with a polymer binder was electrospun into a nanoﬁbrous mesh
and heat-treated to produce ﬁbers with sizes ranging 84 nm to 640 nm
by varying the sol concentration. The glass nanoﬁber induced the
formation of a bone mineral-like apatite phase on the surface in a
simulatedbodyﬂuid,whichwas attributed to theextremely large surface
area of the nanoﬁber and the consequent ionic reaction with the
surrounding medium (Fig. 4). Moreover, the nanoﬁbrous substrateUN
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Fig. 4. (a) Inorganic nanoﬁber with a bone-bioactive composition (sol–gel glass 70SiO2·25C
bone-bioactivity of the nanoﬁber showing the formation of bone mineral-like apatite on the
(b1) and composition analysis by EDS (b2). Adapted with permission from [70] copyright 20
7 days exhibiting good cell population and active cytoplasmic extension in concert with th
Please cite this article as: J.-H. Jang, et al., Electrospun materials as pot
(2009), doi:10.1016/j.addr.2009.07.008actively supported a population of rat BMSCs and osteogenic differentia-
tion to a level signiﬁcantly higher than that on dense sintered bioactive
glass or PCL polymer nanoﬁber, highlighting the potential of bioactive
glass nanoﬁbers in terms of both morphological and compositional
beneﬁts. A parallel approachhas also been realizedon theproductionof a
range of inorganic nanoﬁbers including hydroxyapatite [71–73], ﬂuoro-
hydroxyapatite [71], and silica nanoﬁbers [74], by using the sol–gel
solution which was mixed with a polymeric binder either with poly
(vinyl pyrrolidone) and poly(vinyl butyral) and subsequent heat
treatment. One elegant study applied the in-situmineralization behavior
of the bioactive glass to the introduction of biomolecules on theTE
D
PR
OO
F
aP·5P2O5) obtained by electrospinning and heat-treatment at 700 °C. (b1,b2) Acellular
nanoﬁbrous surface after soaking in simulated body ﬂuid for 3 days, as observed by TEM
06Wiley-VCH Verlag GmbH & Co. (c) Rat BMSCs grown on bioactive glass nanoﬁbers for
e underlying nanoﬁbrous substrate.
ential platforms for bone tissue engineering, Adv. Drug Deliv. Rev.
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ARTICLE IN PRESSnanoﬁber surface [75]. Cell-adhesive ﬁbronectin was effectively coupled
with apatite mineral onto the surface of bioactive glass nanoﬁber which
demonstrated signiﬁcant enhancement in the initial osteoblast adhesion
and spreading.
However, regardless of their attractive bone-bioactivity, electrospun
nanoﬁbers of inorganic materials, including calcium phosphates and
bioactive glasses, may have limited use as tissue regeneration matrices
on account of their brittleness. Moreover, post heat-treatment can limit
their drug delivery potential. In this respect, future knowledge and
advanced technology need to be developed in order to overcome the
disadvantages of bone-bioactive inorganic nanoﬁbers as well as to
identify appropriate uses as bone tissue engineering matrices. At the
moment, nanoﬁbrous inorganic materials are being studied as nano-
ﬁllers for the production of nanocomposite scaffolds with degradable
polymers [76,77]. In particular, electrospun nanoﬁbrous bioactive glass,
being used as a novel inorganic nanocomponent, is well homogenized
with collagen or a PLLA solution to produce uniform scaffolds and
membranes, ultimately improving the bone-bioactivity of the organic
phase and osteogenic differentiation and cellularmineralization (Fig. 5).
The approach, which aimed to combine the bone-bioactivity of the
inorganic component with shape-formability of the organic phase,
highlights the useful application of the electrospun inorganic nanoﬁbers
as a bone-bioactive nanocomponent.
3.3. Polymer-inorganic composite/hybridized nanoﬁbers
Combining degradable polymers with bioactive inorganic materi-
als during the course of electrospinning is considered a fascinatingUN
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Fig. 5. Use of electrospun bioactive glass as an inorganic nanoﬁller for the production of nan
homogenized with a collagen solution (a1) and further dried into a nanocomposite (a2,
Nanocomposite with PLLA showed the permeation of a PLLA solution well into the inte
nanocomposite (b2). The bone-bioactivity of the nanocomposites with collagen and PLLA
immersed in SBF. Adapted with permission from [76,77] copyright 2007 Wiley Interscience
Please cite this article as: J.-H. Jang, et al., Electrospun materials as pot
(2009), doi:10.1016/j.addr.2009.07.008RO
OF
and reasonable way of generating nanoﬁbers with the appropriate
properties targeted for bone regeneration. The inorganic phase may
act to improve the biological properties of polymeric nanoﬁbers, such
as cell compatibility and bone forming process, involving the
osteogenic differentiation and calciﬁcation of bone matrix. Moreover,
given that the brittleness of inorganic materials is a major limitation
to their use as suitable cell substrates, the introduction of a polymeric
phase should provide some degree of mechanical ﬂexibility. In
addition, the fact that there is no need for thermal treatment because
of the binding polymer matrix is another attractive point for its use in
drug delivery systems. Basically, the bone ECM is a type of composite
constituted mainly of collageneous ﬁbers embedded with hydro-
xyapatite nanocrystallites, which highlights the need for the devel-
opment of nanocomposites mimicking bone structure [35].
In practice, the combinatorial/synergistic mechanical and biological
properties of polymers and inorganics have been well documented in
cases of porous scaffolds and membranes [78]. The ideas beyond those
nanocomposites might well be applied to nanoﬁbrous systems.
However, it should also be noted that the electrospinning of organic–
inorganic compounds requires special consideration in the preparation
of solutions. Some elegantmethods have beenused to produce organic–
inorganic composite nanoﬁbers by electrospinning. One example is the
gelatin-hydroxyapatite nanoﬁber, which was designed to mimic the
bone ECM, wherein gelatin and hydroxyapatite precipitates were
dissolved in an organic solvent and subsequently electrospun to
produce nanoﬁbers with, hundreds of nanometers in diameter (Fig. 6)
[79]. Hydroxyapatite nanocrystallites were evenly distributed in the
gelatin matrix within the nanoﬁbrous morphology, which wasTE
D
P
ocomposites with collagen (a1–a3) and PLLA (b1,b2). The nanoﬁbrous component was
a3), showing an inter-organized glass nanoﬁber (BGNF) and collagen ﬁbers (a2,a3).
rspacings of the nanoﬁbrous network (b1), which was pressed to produce a dense
was signiﬁcantly enhanced showing the induction of a bone mineral-like phase when
Co.
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Fig. 6. (a) Experimental procedure to generate gelatin-apatite bone-mimicking nanoﬁbers and (b1,b2) TEM image of a gelatin–20%apatite nanoﬁber and the organization of apatite
within the gelatin matrix (apatite crystalline pattern revealed in the inset). (c) Osteoblastic cells exhibiting higher levels of alkaline phosphatase phenotypic expression on the
nanocomposite nanoﬁbers after 7 days of culturing. Adapted with permission from [79] 2005 Wiley-VCH Verlag GmbH & Co.
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attributed to the role of the gelatin amino acid sequences modulating
the precipitation of hydroxyapatite crystals. On the other hand, when
hydroxyapatite nanopowders were mixed directly with a gelatin
solution, electrospinning into nanoﬁbers was impeded signiﬁcantly
resulting in a number of beads. The organized hybrid matrix showed
signiﬁcant enhancement in osteoblastic differentiation, and was
proposed for use as a guided tissue regenerationmembrane in dentistry.
This approach was also realized in the collagen
^
–
^
hydroxyapatite system
to generate a nanoﬁbrous matrix to better mimic the bone ECM [80] as
well as applied toother composite nanoﬁber of chitosan
^
–
^
hydroxyapatite
[81].
Apart from natural polymers, synthetic degradable polymers have
also been used in the electrospinning of composite ﬁberswith bioactive
inorganic materials. However, unlike hydrophilic natural polymers,
which are easier to homogenize and be organized with inorganic
crystallites, degradable synthetic polymers, such as PLA, PCL and PHBV,
present a signiﬁcant challenge in their combination with the inorganic
phases on account of their hydrophobic nature. A recent work by
Fujihara et al. developed PCL–CaCO3 composite ﬁbers with submic-
rometers in size, by introducing ultraﬁne CaCO3 particles (∼40 nm in
size) [82]. Composite ﬁbers containing CaCO3 nanoparticles at 25 and
75 wt.% showed good water afﬁnity and mechanical tensile properties,
as well as directed favorable osteoblastic adhesion and growth, thus
being suggested for use as a guided bone regeneration membrane
(Fig. 7).
However, inorganic nanoparticles generally agglomerate easily and
cannot be intermixed well or homogenized with synthetic polymer
solutions, resulting in bead formation during electrospinning. In an
attempt to overcome this, we recently exploited PLA composite ﬁbers
containing ultraﬁne hydroxyapatite nanocrystallites obtained by a sol–Please cite this article as: J.-H. Jang, et al., Electrospun materials as pot
(2009), doi:10.1016/j.addr.2009.07.008Tgel process (∼35 nm in size) and by introducing a surfactant, 12-hydroxysteric acid (Fig. 8) [83]. The amphiphilic nature of the surfactant
was suggested to act as a stabilizing mediator at the interface of the
hydroxyapatite nanocrystallites and PLA-organic solvent. Bead-free
electrospun ﬁbers were obtained with ﬁber sizes of a few micrometers
wherein the hydroxyapatite nanocrystalliteswell distributedwithin the
PLA matrix. The composite ﬁber was shown to promote the growth of
osteoblastic cells and their phenotype expression to a signiﬁcantly
higher level than on pure PLA ﬁber. Overall, the current electrospinning
of composite ﬁbers has focused mainly on incorporating bioactive
inorganic nanoparticles evenly within a polymeric matrix without
breakingdown theﬁbrousmorphology. This has beenpossible to a large
extent through the introduction of ultraﬁne particles or control of the
level of homogenization.
Instead of introducing particulate forms of the bioactive inorganic
phases within a polymeric solution, degradable and bioactive hybrid
nanoﬁbers were recently produced through the hybridization
approach of using inorganic and organic phases in solution, such as
the sol–gel process [84]. An aqueous solution of gelatin was mixed
with polysilane (3-(glycidopropyl) trimethoxysilane) at various ratios
(siloxane/gelatin=0.5, 1 and 2) containing a small concentration
(2.5 wt.%) of CaCl2, which was hydrolyzed, condensed and then
electrospun into nanoﬁbers. In particular, the involvement of siloxane
groupswithin the gelatin signiﬁcantly improved the chemical stability
of gelatin by forming linkages with amide groups of gelatin to produce
a hybridized network. Moreover, the hybridized nanoﬁbers signiﬁ-
cantly enhanced osteoblastic differentiation, suggesting their poten-
tial use as a bone regeneration matrix (Fig. 9).
The approach of using bioactive inorganic phases in concert with
degradable polymers is continuing to attract attention in ﬁndingential platforms for bone tissue engineering, Adv. Drug Deliv. Rev.
NC
OR
RE
CT
ED
PR
OO
F
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
Fig. 7. (a1,a2) Image of electrospun nanoﬁbers of PCL and PCL/CaCO3 composite and EDS mapping. (b) Tensile stress^
–
^
strain curves of the nanoﬁbers. Reprint with permission from
[82] 2005 Elsevier.
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ARTICLE IN PRESSUsuitable matrices for the regeneration of bone and its interfaced zonewith cartilage [85,86]. Therefore, many more studies are expected to
focus on developing composite nanoﬁbers with new compositions
with suitable mechanical properties and biological functions in bone
regeneration. Although some challenges still remain, such as
morphological and compositional control, including a reduction of
ﬁber size, level of homogenization, and securing mechanical stability,
more promising results are expected to come out from the composite
nanoﬁbers with respect to the polymeric single component.Please cite this article as: J.-H. Jang, et al., Electrospun materials as pot
(2009), doi:10.1016/j.addr.2009.07.0084. Bio-functionalization and scaffolding for tissue engineering
Given that nanoﬁbrous matrices have an extremely large surface
area relative to volume, the surface-related properties of nanoﬁbrous
materials, such as materials release, protein adsorption and cell
adhesion, are very important. Therefore, it is essential to tailor the
surface properties of nanoﬁbers to induce the appropriate biological
reactions. The surface-functionalization of the nanoﬁbers, as a post-
treatment following the electrospinning process is another importantential platforms for bone tissue engineering, Adv. Drug Deliv. Rev.
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Fig. 8. (a) Schematic diagram showing the experimental design of the HA–PLA biomedical nanocomposite ﬁber mediated with HSA surfactant through the electrospinning process.
(b1–b4) Electron morphology of the HA–PLA nanocomposite ﬁber electrospun under different conditions: HA commercial powder without HSA (b1), HA sol–gel powder without
HSA (b2), HA sol–gel powder with 0.1% HSA (b3), and concentration of (b4) 12.5% was thickened to 25% by evaporation of the solvent (b5). (c) TEM morphology of the
nanocomposite electrospun ﬁber consisting of HA sol–gel powder and PLA obtained with the mediation of 0.1% HSA. Fiber image in the inset prepared as an ultrathin ﬁlm (b100 nm)
using a microtome reveals the dispersion of HA ﬁne particles within the PLA matrix. (d) ALP activity expressed by the cells after culturing for 7 days. A glass coverslip was used as a
ﬁber-supporting substrate. Data on tissue culture dish was included as a control. The cell seeding density was 1×104/ml. The data is reported as the mean±std., for n=6, and a
statistical comparison by ANOVA one-way analysis showed signiﬁcant differences between the HA–PLA ﬁber and PLA ﬁber at pb0.01 (⁎) and 0.001 (⁎⁎). Reprint with permission
from [83] 2006 Wiley Interscience Co.
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COarea for regulating and improving the potential of nanoﬁbers as a cellmatrix. The initial cell adhesion and growth, osteogenic differentia-tion and matrix synthesis, and therapeutic stimulations can be tunedby bio-functionalization of the surface, which include the surface
coverage with bone-reactive materials and spatially distributed
conjugation with macromolecules, such as proteins, peptides and
antibiotics. In the latter case, surface-tailored nanoﬁbers will have
therapeutic impact as an implantable drug delivery system [6].
However, in order to gain intended biological performance, the
surface conjugatedmolecules shouldmaintain their biological activity
and exhibit therapeutic functioning in a timely and proper manner.
However, in such systems for long term delivery, drugs sometimes
need to be encapsulated within the nanoﬁber to elicit therapeutic
effect in a sustained manner.
The improvement in 3D scaffolding techniques is another
challenge in electrospun nanoﬁbers if they are to ﬁnd potential use
in bone tissue engineering. Electrospun nanoﬁbrous meshes containPlease cite this article as: J.-H. Jang, et al., Electrospun materials as pot
(2009), doi:10.1016/j.addr.2009.07.008small sized channels, at best a few micrometers in size, which can
restrict cell migration and angiogenesis to form neo-blood vessels.
Many recent attempts have been made to produce macropores within
or to construct 3D tissue analogs with electrospun nanoﬁbers, which
may extend their potential use in bone tissue engineering.
4.1. Surface functionalization
Speciﬁc focus has recently been made on utilizing bone mineral
phase in surface-tailoring of polymeric nanoﬁbrous matrices which
targeted for bone regeneration. As the bone mineral-like calcium
phosphates, mainly hydroxyapatite phase, have good biocompatibility
related to cell afﬁnity and osteogenic regulation, a surface treatment of
degradable polymeric nanoﬁbers with a mineral phase is a promising
route for up-regulating the bone cell functions [87–89]. A recent study
mineralized a PCL nanoﬁbrous surface with hydroxyapatite using a
series of surface-modiﬁcation steps involving the activation ofential platforms for bone tissue engineering, Adv. Drug Deliv. Rev.
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Fig. 9. (a) Morphology of gelatin–siloxane hybridized nanoﬁbers (gelatin:polysilane=1:1, CaCl2 addition=2.5 wt.%). (b1,b2) MC3T3-E1 growth on the hybridized nanoﬁber after
3 days (scanning electron microscopy (b1) and confocal laser scanning microscopy (b2)). (c) Alkaline phosphatase activity of osteoblastic cells on the nanoﬁbers showing a
signiﬁcantly higher level on the hybridized ones (ANOVA). Reprint with permission from [84] 2008 Wiley Interscience Co.
12 J.-H. Jang et al. / Advanced Drug Delivery Reviews xxx (2009) xxx–xxx
ARTICLE IN PRESSUN
Cnanoﬁbers in an alkaline solution (2 N NaOH) to generate carboxylic
groups, followed by alternate dipping in Ca and P-rich solutions
(150 mM of Ca2+ and HPO4−) to allow mineral nucleation followed by
further soaking in a Ca–P pseudo saturated solution (simulated body
ﬂuid) [87]. The mineralized PCL nanoﬁber showed active osteoblastic
responses, such as cell adhesion and growth, and signiﬁcantly higher
expression levels of the genes related to bone ECM than those on pure
PCL nanoﬁber [87] (Fig. 10). Through surface mineralization, sig-
niﬁcant osteogenic induction was also observed on the periodontal
ligamentﬁbroblasts, highlighting themineralizedpolymeric nanoﬁber
for use as a guided bone regeneration membrane [88].
A similar approach has also been found in other degradable
polymers, including PLA (L- and DL-type), wherein the mineral
induction was facilitated more easily by treatment in an alkalinePlease cite this article as: J.-H. Jang, et al., Electrospun materials as pot
(2009), doi:10.1016/j.addr.2009.07.008solution [89] or by incorporating calcium [90]. When collagen was
added to the PLA nanoﬁber, hydroxyapatite induction was possible
without treatmentwith an alkaline solution, where collagen plays a key
role in mineralization [91]. The hydroxyapatite mineral phase obtained
by the solution-mediated process is generally poorly crystallized and
carbonated, being similar in composition and structure to the native
bone mineral, which is thus believed to regulate a series of biological
reactions in a favorable manner, including the selective adsorption of
bone-associated proteins, osteogenic stimulation of progenitor
^
/
^
stem
cells, and the acceleration of subsequent bone formation. Moreover,
modiﬁcation ofmineralized nanoﬁberswith bio-functionalmolecules is
expected to be a promising area of future research because the apatite
mineral has strong afﬁnity to certain bone-speciﬁc proteins which
contribute enhanced bonding to bone tissue [92,93].ential platforms for bone tissue engineering, Adv. Drug Deliv. Rev.
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Fig. 10. (a1,a2) Morphology of the surface-mineralized PCL nanoﬁbrous matrix obtained by a series of solution-mediated mineralization steps involving activation in an alkaline
solution, alternate soaking in Ca- and P-solutions, and immersion in SBF. (b1,b2) Initial osteoblastic cell response showing better spreading behavior on the mineralized PCL
nanoﬁber (b1) than on pure PCL nanoﬁber (b2) at 8 h
^
of culturing. (c) Cell viability and (d) expression of bone-associated genes were signiﬁcantly enhanced by surface
mineralization. Adapted with permission from [87] 2007 Wiley Interscience Co.
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COMore general than the mineral phase is the bioactive macromole-cules that have been introduced on the surface of polymeric nanoﬁbers,
including proteins, peptides and drugs, to regulate and improve speciﬁc
biological functions. Nonetheless, few studies have examined the
applicability of macromolecules in bone regeneration area. A few
studies used RGD (Arg-Gly-Asp) peptides to adhere onto polymeric
surfaces and reported the biological effects of the cell adhesive ligands,
such as adhesion, spreading and growth, using a range of cell types
[94,95]. Fibroblast adhesion, spreading and growth were enhanced
when the GRGDY peptide was immobilized on PLGA and its copolymer
with PLGA-b-poly(ethylene glycol) (PEG)-NH2 nanoﬁber [94]. Given
that the major weakness of the synthetic polymeric surface is the poor
cell afﬁnity, the use of adhesive proteins or peptides is believed to be an
appropriate way of improving the initial bone cell responses and
possibly further biological steps. Our recent study also developed thePlease cite this article as: J.-H. Jang, et al., Electrospun materials as pot
(2009), doi:10.1016/j.addr.2009.07.008surface of poly(lactic-co-caprolactone) (PLCL) nanoﬁbers by covalently
linking with a ﬁbronectin peptide containing a central cell binding
domain to improve the initial cell adhesion and spreading behavior of
osteoblastic cells. Parallel applications were also suggested using bone
target proteins and peptides, such as growth factors and bone
morphogenetic protein family. Together with the types of macromole-
cules, the selection of a coupling method and the maintenance of their
biological activity should be fully considered to gain the optimal
performance of biomolecules on a nanoﬁber surface.
4.2. Drug encapsulation within nanoﬁbers
When macromolecules are coupled onto the surface of nanoﬁbers,
maintenance of their chemical stability and biological activity for
prolonged time course is of special importance. Therefore, theential platforms for bone tissue engineering, Adv. Drug Deliv. Rev.
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ARTICLE IN PRESSencapsulation of drugs within the nanoﬁbers might be favored, which
will be particularly useful for controlled release systems. In this case, the
encapsulationmethod and drug efﬁciency aswell as the eluting proﬁles
need to be designed and investigated carefully. In particular, the drugs
chemically bound to thematrix with respect to those physically mixed
^
/
^
adsorbedmay sustain their elution for longer period, and depending on
the encapsulated status, drug release kinetics is greatly affected. A range
of drugs have been encapsulated within the nanoﬁbers of polymers,
including antibiotics, bonemorphogenetic protein, and even genes [96–
101]. Although not all were targeted for bone tissue, the method is
believed to be suitable for bone reconstruction. Poly(lactic-co-glycolic
acid) (PLGA) nanoﬁbers mixed with a hydrophilic block copolymerUN
CO
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EC
Fig. 11. (a) Illustration of the gene-delivering nanoﬁber scaffold showing the DNA ﬁrst sec
generate a DNA-incorporated nanoﬁber. (b1) SEM image of the nanoﬁber incorporating DNA
chitosan nanoparticles. (c) In vitro release proﬁle of DNA from nanoﬁbers incorporated with
with permission from [101] copyright 2007 Elsevier.
Please cite this article as: J.-H. Jang, et al., Electrospun materials as pot
(2009), doi:10.1016/j.addr.2009.07.008were incorporated with antibiotics (Mefoxin®, cefoxitin sodium), and
the nanoﬁber mesh showed potential to entrap drugs and then release
them in a sustained manner, ultimately inhibiting bacterial activity
[96,97]. For the speciﬁc delivery of osteogenic signals, BMP-2 was
encapsulated directly within the blending polymer of silk and
polyethylene oxide to show enhanced mesenchymal stem cell differ-
entiation into the osteogenic linage and calciﬁcation [98]. For gene
delivery within the nanoﬁbrous matrix, DNA was ﬁrst encapsulated
within a block copolymer polylactide–poly(ethylene glycol), whichwas
further electrospun in concert with the PLGA solution [100]. The results
showed that the nanoﬁbrous matrix delivered DNA that was capable of
cellular transfection and encoding proteinβ-galactosidase [100]. RecentTE
D
PR
OO
F
ured within the chitosan nanoparticles and then electrospun with a PLGA solution to
/chitosan. (b2) Enlarged image of the ﬁber cross-section revealing the presence of DNA/
DNA/chitosan nanoparticles, showing continuous release for up to ∼60 days. Adapted
ential platforms for bone tissue engineering, Adv. Drug Deliv. Rev.
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ARTICLE IN PRESSstudyon speciﬁc targeting for bone tissuehas been reportedbyNie et al.,
where they used the PLGA/hydroxyapatite composite nanoﬁbers to
deliver BMP-2 plasmid DNA [101]. In particular, the DNA was pre-
loaded within chitosan before electrospinning the PLGA/hydroxyapa-
tite solution. The results demonstrated that the nanoﬁber encapsulated
with DNA/chitosan had higher cell attachment and viability as well as
more desirable transfection efﬁciency than the nanoﬁber surface-
adsorbed with naked DNA or surface-adsorbed with DNA/chitosan
(Fig. 11) [101]. Pre-encapsulating genes within nano-vehicles before
electrospinning is thus considered an appropriate way of securing the
biological stability of genes and improving the transfection efﬁciency.
Although studies on gene deliverywith nanoﬁbrousmatrices are still in
the early stages, this area may be a future direction in the bone
regenerative medicine using the nanoﬁbers [102].
Novel designing of the electrospinning apparatus permits advances
in the drug delivery technology. A dual tip (syringe) apparatus, so-calledUN
CO
RR
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Fig. 12. Scaffolding techniques of the electrospun nanoﬁbers: (a1,a2) Salt particle incorpo
∼100 µm in size. Adapted with permission from [109] 2008 copyright Mary Ann Liebert. (b1,b
of the process and (b2) generated micro-nanoscaffold. Adapted with permission from [1
(c1) knitted conducting polymer collector and (c2,c3) produced patterned scaffolds. Adapt
Please cite this article as: J.-H. Jang, et al., Electrospun materials as pot
(2009), doi:10.1016/j.addr.2009.07.008co-axial electrospinning, which was designed to produce a core–shell
structure of the nanoﬁber, was reported to contain and release drugs
more efﬁciently [103,104]. Drug-containing solution to be placed in the
core part was electrospun simultaneously with the material solution to
be allocated at the outer layer. In this case, while the inner solution
affects thedrug loadingefﬁciencyand stability, theproperties of the shell
layer cancontrol thedrug release proﬁle. Furthermore, dependingon the
drug properties, suitable materials and solutions should be selected for
the core–shell nanoﬁber structure.Modulation of themorphological and
chemical properties of nanoﬁber materials is the key to controlling the
drug delivering ability [9]. This drug delivering potential greatly
strengthens the ability of artiﬁcial scaffolds to guide osteogenic
differentiation of stem cells and to generate bone analogs in bone tissue
engineering approach. As new knowledge on novel materials becomes
available, more extensive works are expected in tissue engineering
nanoﬁbrous scaffolds with therapeutic design targeted for bone.TE
D
PR
OO
F
ration and leaching method; (a1) schematic diagram and (a2) generated macropores
2) Electrospinning combined with a direct depositionmethod; (b1) schematic diagram
12] 2008 copyright Acta Materialia. (c1–c3) Patterned conducting polymer method;
ed with permission from [113] 2007 copyright Wiley-VCH Verlag GmbH & Co.
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ARTICLE IN PRESS4.3. Scaffolding for cell growth and tissue engineering
More widespread use of electrospun nanoﬁbers for tissue engineer-
ing applications has been a challenge due to their difﬁculty in 3-
dimensional shaping and macroporous scaffolding. Processed by a type
of line-of-sight approach, electrospun ﬁbers are ﬁrst gathered in the
form of a 2-dimensional sheet and then piled up 3-dimensionally with
increasing spinning time. Although some collector designs help shape
nanoﬁbers into simple forms, such as tubular forms, much more
complex shapes are still on demand [105]. Above all, interconnected
macro-pores are essential for vascularization in order to supply oxygen
and nutrients, provide sufﬁcient space for cell ingrowth and drain the
consumedmetabolites [106,107]. Although the electrospunnanoﬁbrous
structure generates a network of open-pores, the pore sizes are about
the same order of the ﬁber sizes, i.e., at best a few micrometers. Some
studies provided evidence of in vitro cell penetration and in vivo tissue
formation within the nanoﬁbrous network, where thin membranousUN
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EC
Fig. 13. Layer-by-layer approach for tissue engineering: (a) Schematic diagram of the on-site
varied during cell assembly to create a customized ﬁnal 3D construct. (b1,b2)Multi-layered c
DAPI-stained cross sections of ﬁber–cell constructs cultured for 2 days. Nuclei, blue. The ﬁber
permission from [114] 2008 copyright Mary Ann Liebert.
Please cite this article as: J.-H. Jang, et al., Electrospun materials as pot
(2009), doi:10.1016/j.addr.2009.07.008substrates were used [57,108]. In particular, the ex-vivo culturing of
tissue cells within nanoﬁbers to construct uniform cell-material
constructs is a signiﬁcant challenge. Moreover, the reconstruction of
larger and complex-shaped bone defects requires 3-dimensional
shaping of the nanoﬁbrous scaffolds with interconnected macropores.
Otherwise, new technological tools to develop 3-dimensional tissue
mimicking cell-nanoﬁber constructs should be explored.
Some studies have reported a level of success on the scaffolding of
electrospun nanoﬁbers [109–113] (Fig. 12). Salt particles were
incorporated within the polymer nanoﬁbrous matrix, which then
leached out to generate some macropores [109]. Furthermore, salt
leaching and gas foaming techniques have been combined to produce
some macropores within a clay-reinforced PLA nanoﬁbrous struc-
ture [110]. One approach used the microﬁbrous mesh as a rigid
supporting structure uponwhich the nanoﬁbrous networkwas covered
by electrospinning to produce a micro-nano ﬁbrous scaffold [111].
However, the process can only produce a scaffold with a limitedTE
D
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F
layer-by-layer cell assembly on the electrospun ﬁbers. Both ﬁber and cell layers can be
ell–ﬁber constructs with two different ﬁber layer thicknesses. Fluorescent micrograph of
s were labeled with FITC (green), and the cells were stained blue by DAPI. Adapted with
ential platforms for bone tissue engineering, Adv. Drug Deliv. Rev.
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thickness. A similar approach aimed at producing a thicker nanoﬁbrous
network on a microﬁbrous structure using alternate processes of
electrospinning anddirect deposition of polymermelt [112]. Ultimately,
those approaches attempted to combine the 3D scaffolding merit of a
microﬁbrous support with a nanoﬁbrous network. The cell responses
were signiﬁcantly enhanced when the electrospun nanoﬁbrous net-
work was present on the microﬁbrous scaffold. Modifying a collector
part with conducting patterned polymers made it possible to pattern a
nanoﬁbrous network [113].
One recent report showed the engineering of 3D tissue constructs
using a thin nanoﬁbrous substrate [114]. A tissue-mimicking 3D
construct was developed by the alternate stacking of cells and thin
nanoﬁber substrate (Fig. 13). The idea was to culture the cells on the
thin 2D nanoﬁbrous substrate and then build 3D cell-nanoﬁber
constructs using a layer-by-layer approach. As the cells can easily
penetrate a thin layer of nanoﬁbers, the method was proposed to
mimic the native 3D tissue structure. Although suggested particularly
effective for engineering layered tissues, such as skin, the approach
can also be applied to the elaboration of 3D bone structure.
As described above, some technological advances are in progress to
fully utilize the electrospun nanoﬁbers in tissue engineering applica-
tions, including bone regenerative area. Given that the scaffolds for
bone tissue engineering need to be qualiﬁed for speciﬁc mechanical
properties as well as for biological compatibility, the 3D structural
design of nanoﬁbers and their scaffolding with tissue cells should be
considered carefully in order to achieve properties analogous to the
native bone ECM. Although few studies have been carried out using a
nanoﬁbrous matrix in bone tissue engineering, promising outcomes
may be reported in the near future.
5. Concluding remarks
Asigniﬁcant amountof researchhas beendirected toelectrospinning
nanoﬁbrous materials targeted for bone regeneration. The selection of
materials with the appropriate composition is of utmost importance in
the successful generation of bone ECM mimicking matrices suitable for
neo-bone formation. As described in this review, a range of degradable
polymericmaterials have demonstrated utility for bone regeneration. In
particular, recent efforts have been focused on the incorporation of
bioactive inorganic nanoparticleswithin thepolymeric phase reapingup
the combinatory roles of bone-bioactivity and rigidity of inorganic phase
and degradability and shape-formability of polymers.Moreover, there is
increasing research on the surface functionalization of nanoﬁbers, such
as mineralization of the polymeric surface and coupling with proteins/
peptides, to regulate cell functions from the initial cell adhesion to
osteogenic stimulation of progenitor
^
/
^
stem cells.Materials that can elicit
therapeutic effects by incorporating bio-signaling molecules within the
nanoﬁbers, such as antibiotics and proteins and genes pre-loaded in
nanocapsules, hold great promise as scaffolds with drug delivery
potential. To make full use of 3D cell culturing and tissue engineering,
there has been considerable research aimed at developingmacroporous
morphology as well as shaping the nanoﬁbrous structure by apparatus
design and engineering cell-material constructs.
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